positive

GLP-1 wave

Demand Increase: Being fat is out. • Substitution / Disruption: HIMS offers direct to consumer GLP-1 treatment and LLY produces it.

Pressure Strength 0.50

Boom Scenarios

HIMS Expansion

medium

Hims expands its market reach through strategic acquisitions and partnerships, increasing the availability of GLP-1 treatments.

GLP-1 Expansion to Other Diseases

medium

Clinical trials demonstrate GLP-1's efficacy in treating other chronic conditions, expanding its market beyond obesity.

GLP-1 Widespread Adoption

high

Increased awareness and positive clinical outcomes lead to rapid adoption of GLP-1 treatments across a broader patient base.

LLY Innovations

high

LLY introduces new formulations or delivery methods for GLP-1 treatments, enhancing their effectiveness and convenience.

Public Health Campaigns

high

Government-led public health campaigns promote the benefits of GLP-1 treatments, increasing awareness and demand.

Invalidation Scenarios

New Drug Efficacy

medium

A new drug or therapy is developed that outperforms GLP-1 in treating obesity, leading to a decline in its usage.

Regulatory Changes

medium

New regulations are introduced that restrict the use of GLP-1 treatments, reducing market access.

Public Fat Acceptance

low

Cultural shift towards acceptance of a variety of body types reduces demand for weight loss treatments.

GLP-1 Side Effects

high

Severe side effects are reported in a significant number of patients using GLP-1 treatments, causing regulatory scrutiny and reduced prescriptions.

Patent Expired

high

Key patents on GLP-1 treatments expire, leading to increased competition and reduced pricing power for original manufacturers.